title: [Prospective study on surface-enhanced laser desorption/ionization protein fingerprinting for diagnosing gene polymorphism leading to drug resistance drift: sequential therapy with a platinum-based regimen and gefitinib for non-small cell lung cancer].
abstract: BACKGROUND
  This study aims to observe the long-term effects of sequential therapy with a platinum-based regimen and gefitinib for non-small cell lung carcinoma (NSCLC) with failed chemotherapy under the guidance of surface-enhanced laser desorption/ionization (SELDI).
  
  
  METHODS
  Nine NSCLC patients with failed chemotherapy and ≤15% abundance of M/Z: 8,693±50H+ were selected. The patients were administered with 250 mg of gefitinib (p.o., once a day). During the therapy, SELDI was applied every 2 months. If the M/Z: 8,693±50H+ abundance was >25%, chemotherapy was applied; if the abundance was ≤15%, gefitinib (p.o.) was applied. In between, we chose gefitinib according to the mass and tumor markers. On the base, we sequentially applied the drug and observed the total survival time.
  
  
  RESULTS
  Follow-ups until December 2010 revealed that the median overall survival time of the nine patients was 27 months (10 months-66 months).
  
  
  CONCLUSIONS
  The treatment benefit ratio and benefit time of anti-NSCLC drugs can be improved by SELDI fingerprinting.
authors: Department of Geriatric Medical Oncology, Shan Xi Da Yi Hospital, Taiyuan 030032.
authors: Li'na
authors: L
authors: Ji
authors: Yi
authors: Y
authors: Pei
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D005500:Follow-Up Studies; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010984:Platinum / Q000627:therapeutic use; D011110:Polymorphism, Genetic; D011446:Prospective Studies; D040901:Proteomics; D011799:Quinazolines / Q000627:therapeutic use; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D010984:Platinum; D000077156:Gefitinib